



NEAL
GERBER
EISENBERG

Thomas J. Campbell Jr.

Partner | Intellectual Property

OVERVIEW

Tom represents clients in patent and trademark prosecution, intellectual property litigation, and post-grant patent challenges before the Patent Trial and Appeal Board (PTAB). Tom has a broad base of experience in various technological and business areas, particularly in pharmaceutical, biotechnology, chemical and medical device inventions. He drafts invalidity opinions, investigates freedom to operate, counsels on strategic portfolio management, and conducts due diligence investigations prior to acquisition or merger.

He has extensive scientific research experience in both industry and academic settings. Tom worked as a pharmacologist in the Advanced Technology Division of Abbott Laboratories to identify safe and efficacious drug candidates. His skill as a researcher was recognized when Abbott honored him with its Global Pharmaceutical Research and Development Award for Leadership. Tom also conducted various chemical and biological research both at the University of Notre Dame and University of Chicago. His chemical research was directed toward organometallic catalysis. His biological research involved investigating the underlying causes of diabetes — including the molecular biology of ion channels and the role genetics plays in beta cell dysfunction. This experience as a scientist enables Tom to effectively communicate with clients and inventors seeking patent protection or counseling.

Tom has published peer-reviewed scientific journal articles, including multiple articles in the *Journal of Medicinal Chemistry* and the *Journal of Cardiovascular Pharmacology*. Tom has been published in the *National Law Journal* and coauthored book chapters in the American Bar Association's



tcampbell@nge.com

D. (312) 269-5357

F. (312) 980-0867

EDUCATION

Johns Hopkins University (M.S.,
Biotechnology, 2023)

DePaul University College of Law
(J.D., 2009) *cum laude*

University of Notre Dame (B.S.,
Biochemistry, 2002)

ADMISSIONS

Illinois

U.S. Patent and Trademark Office



NEAL
GERBER
EISENBERG

publications *ANDA Litigation* and *Pre-ANDA Litigation*. He is also often sought out for commentary and counseling on emerging trends and proposed rules relating to PTAB trials.

He has represented pro bono clients through the DePaul Technology/Intellectual Property Clinic, Equip for Equality and Lawyers for the Creative Arts. He is also a trained mediator and has been certified by the Center for Conflict Resolution in Chicago.

Tom has been listed in the 2016-2020 editions of *Illinois Super Lawyers* as a Rising Star and every edition of *Best Lawyers in America* since 2021 for his expertise in Patent Law

EXPERIENCE

Transactional

- Drafted and prosecuted patent applications on pharmaceutical and medical device inventions useful for the treatment of cardiovascular, renal, oncology, autoimmune, neurological, and viral diseases.
- Prosecuted patent applications directed to diagnostic medical devices.
- Prosecuted patent applications directed to nutritional supplements and medical food.
- Prosecuted patent applications directed to green technology where biomass is converted into transportation fuels.
- Conducted due diligence investigations for pharmaceutical, biotechnology, medical device and green technology clients prior to acquisition, licensing, or investment.
- Conducted due diligence investigations for clients in the chemical arts, including industrial plastics and hydraulic fracturing.
- Conducted evaluations of litigation and AIA trials for clients prior to investment.
- Drafted freedom-to-operate and patentability opinions for pharmaceutical, biotechnology, medical device and chemical inventions.
- Drafted inter-institutional agreements, licenses, operating agreements, assignments, material transfer agreements and other contracts involving research and development.
- Counseled start-up clients, including e-commerce companies, on patent portfolio strategy and management.



NEAL
GERBER
EISENBERG

Litigation

- Represented life science clients in federal district court regarding in patent litigation involving drug eluting stents and an ADHD medication.
- Represented life science client in federal district court regarding trade secret litigation involving stem cell technology.
- Represented life science client in federal district court regarding alleged breach of consent decree in technology relating to use of mutant proteins.
- Represented Patent Owners and Petitioners in *Inter Partes* Review and Covered Business Method Review before the Patent Trial and Appeal Board.
- Defended clients in investigations before the International Trade Commission in matters involving a proprietary coolant chemical and a design patent to a vehicle.

RECOGNITIONS

- *Illinois Super Lawyers*, "Rising Star" in "Intellectual Property," 2016-2020
- *Best Lawyers in America*, Patent Law, since 2021

NEWS & INSIGHTS

April 22, 2025 Event

NGE Sponsors New Mexico Tech's "Inventors & Entrepreneurs Workshop"

August 15, 2024 Firm News

60 Neal Gerber Eisenberg Attorneys Included in 2025 *Best Lawyers In America*

July 17, 2024 In The Media

How Proposed Drug Pricing and Patent Reform Bills Will Impact US Pharma Innovation

May 21, 2024 Event

NGE Attends the ACI Advanced Summit on Life Sciences Patents Conference

May 9, 2024 Publication

United States Patent & Trademark Office Proposes Rule that Would Limit Patent Owner's Enforcement Rights of Patents Subject to a Terminal Disclaimer

August 17, 2023 Firm News

55 Neal Gerber Eisenberg Attorneys Included in 2024 *Best Lawyers In America*

June 9, 2023 Event

Firm Hosts Intellectual Property 102 Webinar Series



NEAL
GERBER
EISENBERG

November 14, 2022 Publication

Thomas Campbell Article on SCOTUS and the Scope of Enablement in *Amgen v. Sanofi* Published in *IPWatchdog*

August 18, 2022 Firm News

60 Neal Gerber Eisenberg Attorneys Included in 2023 *Best Lawyers*

December 27, 2021 Publication

Method-of-Treatment Patents: Increasing Value & Risk

August 18, 2021 Firm News

52 Neal Gerber Eisenberg Attorneys Included in 2022 *Best Lawyers*

September 1, 2020 Publication

ANDA Litigation: Strategies and Tactics for Pharmaceutical Patent Litigators

August 19, 2020 Firm News

46 Neal Gerber Eisenberg Attorneys Included in 2021 *Best Lawyers*

February 3, 2020 Firm News

Illinois Super Lawyers 2020 Recognizes 39 Neal Gerber Eisenberg Attorneys

July 31, 2018 Publication

Pre-ANDA Litigation: Strategies and Tactics for Developing a Drug Product and Patent Portfolio

July 9, 2018 Firm News

41 Neal Gerber Eisenberg Attorneys Listed in 2016 Illinois Super Lawyers

July 6, 2018 Firm News

Neal Gerber Eisenberg Welcomes Four Attorneys to Partnership in Its Intellectual Property and Litigation Groups